MTHFR Gene Mutations and Multiple Sclerosis: Is There a Connection?

MTHFR Gene Mutations and Multiple Sclerosis: Is There a Connection?

Katie Stone - Naturopath

Written By:

Katie Stone - Naturopath
Dr. Conor Sheehy - PharmD, BCPS

Medical Reviewer:

Dr. Conor Sheehy - PharmD, BCPS
Kari Asadorian - Bachelor of Science in Nursing

Edited By:

Kari Asadorian - Bachelor of Science in Nursing

Updated On:

May 20, 2025

Table of Contents

    MTHFR Gene Mutations and Multiple Sclerosis: Is There a Connection?

    Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous system (CNS) that leads to CNS inflammation and demyelination of nerve axons. MS affects about 2.8 million people1 worldwide and around 1 million people2 in the US.


    Genetic factors3 have long been suspected in MS, and recent studies have provided evidence of a link to MTHFR polymorphisms.


    A major factor in the development of MS is elevated homocysteine, which causes dysregulation of the blood-brain barrier4 and endothelial dysfunction. Homocysteine also contributes to the damage of neurons5 through excitotoxicity (excessive stimulation) and apoptosis of neurons. The result is neurodegenerative brain damage, which plays a leading role in the progression of MS.


    This article will explain the pathophysiology of MS and how it may be linked to MTHFR genetic mutations. We will also discuss how an MTHFR polymorphism can increase the risks of developing MS and potential options for treatment and prevention.

    What is Multiple Sclerosis?

    MS is a neurodegenerative disease in which the immune system attacks myelinated axons6 in the central nervous system. Specifically, the immune system attacks the insulating layer or sheath that protects nerves fibers, including those in the brain and spinal cords. This damage disrupts the flow of information between the brain and the body.


    Symptoms are unpredictable, and each patient is affected differently. Some may suffer only mild symptoms, while others may be unable to write, speak, or walk. Most patients suffer initial episodes of reversible neurological deficits, often followed by progressive neurological deterioration over time. Up to 50% will need help walking7 within 15 years after the onset of the disease.


    When diagnosed, around 85% of patients will experience a relapsing-remitting form of MS8, characterized by neurological symptoms that continue for hours to days. Relapse symptoms include fatigue, numbness, tingling, blurred vision, double vision or loss of vision, unsteady gait, and weakness.


    Other forms of MS include secondary progressive, primary progressive, and progressive-relapsing.

    Can an MTHFR Gene Mutation Lead to Multiple Sclerosis?

    The cause of MS remains unknown, but research has indicated that it may involve a combination of genetic susceptibility and an external trigger9, such as a virus or environmental factors. This can lead to autoimmune dysfunction in which the immune system attacks the CNS.


    Genetic influences appear to play a major role in the development of MS, mainly in relation to homocysteine. Previous studies have shown that MS patients have elevated levels of homocysteine10, reduced folate, and reduced vitamin B levels. A large meta-analysis showed that MS patients tend to have elevated homocysteine blood levels11 compared to healthy controls.


    Excess homocysteine can increase the sensitivity of neurons to oxidative stress, leading to apoptosis, hypersensitivity to excitotoxicity, and neuronal damage.12


    MTHFR (Methylenetetrahydrofolate reductase) is the enzyme required for metabolizing folate to 5-methyltetrahydrofolate, which is then required for remethylation and conversion of homocysteine to methionine.


    A mutation on the MTHFR gene impairs the ability to process folate13, leading to low folate levels and elevated homocysteine levels, particularly in those who inherit MTHFR variants from both parents.


    The two most common MTHFR mutations include C677T and A1298C14. Both are associated with decreased MTHFR enzyme activity and increased levels of homocysteine. Some studies suggest the C677T has a more severe effect than the A1298C15 variant.


    MTHFR mutations also may result in a three- to four-fold decreased activity of the COMT enzyme,16 which may also play a role in MS inflammation.


    One study showed that MTHFR C677T and A1298C polymorphisms were strongly associated with a higher risk of MS17 in some populations of people. The study also found a higher risk associated with the MTHFR 1298AC genotypes than controls.


    A previous study also found that subjects with the combined 677CT/1298AC heterozygosity had significantly higher homocysteine levels18 than those of C677T heterozygous.


    An Iranian study19 also found that MS patients with the C677T may be prone to higher levels of serum inflammatory mediators and a vulnerability to an earlier age of onset of disease.


    One study indicated no association between the C677T variants and MS, but it did find a significant association between A1298C and MS.20 An Australian study also showed a non-significant increased MS risk21 associated with the C677T variant.

    How Multiple Sclerosis Could Affect Someone with MTHFR

    Multiple sclerosis may amplify some of the symptoms already associated with MTHFR, including fatigue, weakness, impaired sensation, cognitive impairment, and mood changes.

    Nutritional Status

    Gastrointestinal function is ultimately regulated by the brain and spinal cord, which means that neurologic illnesses such as MS may affect digestive function and nutritional status. Several substantial studies have shown that MS patients are often deficient in vitamin A, B12, and D322.


    The C677T variant is significantly associated with vitamin B12 deficiency,23 which may increase the risk of megaloblastic anemia. Low B12 plays a part in many other MTHFR symptoms. It has been linked to neurological and hematological disorders24 such as neural tube defects, cardiovascular diseases, dementia, and some types of cancer.

    Immune Dysfunction

    Although MS is not considered to affect the immune system directly, medications used to treat the disease, such as steroids and immunomodulators, can suppress immune function, increasing vulnerability to infection.25


    Those with low folate levels due to MTHFR are already at risk of reduced immune function. Folate deficiency leads to a reduced response of T lymphocytes26 and antibodies to several antigens. This suggests that those with MS who also have MTHFR may be at greater risk of infection. 

    Can You Reduce the Risk of Getting MS if You Have an MTHFR Gene Mutation?

    Although it is impossible to change genetic determinants, reducing the risk of developing MS may be possible through nutritional supplementation.


    It is already well-established that elevated homocysteine may contribute to the pathogenesis of MS.27


    Managing homocysteine may be key to reducing the risk and progression of MS. Folate and vitamin B12 play critical roles in CNS function28 at every stage of life, especially the conversion of homocysteine to methionine, which is essential for nucleotide synthesis and methylation.


    MTHFR mutations are typically associated with low folate and B12 levels.29


    Folate is intimately involved in healthy nervous system development and function.30 Vitamin B12 is necessary for the production of red blood cells, nervous system maintenance, and the metabolism of fatty acids essential for maintaining myelin.


    Both nutrients are required to properly function the methionine and folate cycles and methylation cycle, and monoamine oxidase production. Dysfunction in monoamine oxidase31 is thought to be responsible for many psychiatric and neurological disorders, including MS.


    Low B12 will lead to methionine and S-adenosylmethionine deficiencies32: both of which are required for myelin synthesis.


    In a study investigating the effect of Vitamin B12 and folic acid33 supplementation on patients with  MS, it was found that the patients’ homocysteine levels decreased along with their risk of developing anemia. As a result, their quality of life also improved.


    Vitamin D status may also contribute to the risk of developing MS. A study followed 182,000 women34 and found that 173 cases of MS. The risk was 40% lower among those women who reported regular use of at least 400 IU/day of vitamin D from supplements.


    Avoiding smoking is also crucial. The risk of developing MS is about 50% higher for smokers35 than people who have never smoked.

    Treatment Options

    The vitamin B complex has been implicated to have a modulatory role in the pathophysiological process of MS. Researchers have suggested close monitoring of folate and vitamin B12 levels in people with MS, as well as supplementation.


    Folic acid and vitamin B12 may have roles in preventing disorders of CNS development, mood disorders, and dementia. Increasing intake of vitamin B12 and folate36 alongside immunotherapy treatments in patients with MS has so far shown to be promising.


    Folic acid supplementation37 (200-300 mcg/day) to patients with MS improved the neurological status of patients, promoted myelin regeneration and the overall general condition and symptoms.


    High B12 supplementation38 in patients with chronic progressive MS resulted in improved visual and brainstem auditory evoked potentials.


    Higher vitamin D levels39 are associated with reduced risk for developing MS and reduced clinical activity in established MS. 

    How Could Supplementation Help?

    While further research into supplementation for MS is pending, it has been indicated that folate and B12 may play a part in preventing and slowing the progression of the disease.


    Although folic acid supplementation has been used in most of the studies mentioned above, folate is a superior form of the nutrient. Folic acid is not recommended for those with MTHFR polymorphisms as it cannot cross the blood-brain barrier, has no coenzyme activity, and must be reduced to tetrahydrofolate form (the metabolically active form) before the body can use it.


    Methylfolate can bypass impaired folate40 metabolism caused by an MTHFR mutation. Unlike folic acid, it can enter the folate cycle directly without the need for further enzymatic modification.


    The Methyl-Life® product range is made with the internationally-patented Magnafolate® PRO, clinically tested as the world’s purest methylfolate41 and the most active form of folate in plasma circulation. Compared with ordinary folate, Magnafolate® PRO was absorbed faster and utilized more quickly in the body.


    In addition, Methyl-Life’s® B12 Complete is ideal for those who are also low in folate or have any form of health condition or gene mutation that may be affecting B12 absorption. B12 Complete combines the three most active forms42 of B12: Methylcobalamin (2,500 mcg), Hydroxocobalamin (1,250 mcg) and Adenosylcobalamin (1,250 mcg). Previous studies43 have suggested that those with genetic mutations affecting B12 absorption might raise their B12 status more efficiently by supplementing with these three naturally occurring forms of B12.

    References

    1. Clare Walton, Rachel King, Lindsay Rechtman, Wendy Kaye, Emmanuelle Leray, Ruth Ann Marrie, Neil Robertson, Nicholas La Rocca, Bernard Uitdehaag, Ingrid van der Mei, Mitchell Wallin, Anne Helme, Ceri Angood Napier, Nick Rijke, Peer Baneke; "Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition"; Multiple Sclerosis Journal; 2020 Nov

      https://journals.sagepub.com/doi/10.1177/1352458520970841

    2. The National Multiple Sclerosis Society; "MS Prevalence"; National Multiple Sclerosis Society; 2025

      https://www.nationalmssociety.org/About-the-Society/MS-Prevalence

    3. C.A. Young; "Factors predisposing to the development of multiple sclerosis"; QJM: An International Journal of Medicine, Vol. 104, Iss. 5, Pgs. 383–386; 2011 May

      https://academic.oup.com/qjmed/article/104/5/383/1517646

    4. Ekaterina Dubchenko, Alexander Ivanov, Natalia Spirina, Nina Smirnova, Mikhail Melnikov, Alexey Boyko, Evgeniy Gusev, Aslan Kubatiev; "Hyperhomocysteinemia and Endothelial Dysfunction in Multiple Sclerosis"; Brain Sci.; 2020

      https://www.mdpi.com/2076-3425/10/9/637

    5. Ekaterina Dubchenko, Alexander Ivanov, Natalia Spirina, Nina Smirnova, Mikhail Melnikov, Alexey Boyko, Evgeniy Gusev, Aslan Kubatiev; "Hyperhomocysteinemia and Endothelial Dysfunction in Multiple Sclerosis"; Brain Sci.; 2020

      https://www.mdpi.com/2076-3425/10/9/637

    6. Jeffery D Haines, Matilde Inglese, Patrizia Casaccia; "Axonal Damage in Multiple Sclerosis"; The Mount Sinai journal of medicine, New York; 2012 Mar

      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142952/

    7. Marvin M Goldenberg; "Multiple Sclerosis Review"; P&T: a peer-reviewed journal for formulary management; 2012 Mar

      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351877/

    8. Marvin M Goldenberg; "Multiple Sclerosis Review"; P&T: a peer-reviewed journal for formulary management; 2012 Mar

      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351877/

    9. Marvin M Goldenberg; "Multiple Sclerosis Review"; P&T: a peer-reviewed journal for formulary management; 2012 Mar

      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351877/

    10. Ramsaransing GSM, Fokkema MR, Teelken A, et al; "Plasma homocysteine levels in multiple sclerosis"; Journal of Neurology, Neurosurgery & Psychiatry; 2006

      https://jnnp.bmj.com/content/77/2/189

    11. Efthimios Dardiotis, Stylianos Arseniou, Maria Sokratous, Zisis Tsouris, Vasileios Siokas, Alexios-Fotios A Mentis, Amalia Michalopoulou, Athina Andravizou, Metaxia Dastamani, Konstantinos Paterakis, Dimitrios Bogdanos, Alexandros Brotis; "Vitamin B12, folate, and homocysteine levels and multiple sclerosis: A meta-analysis"; Multiple sclerosis and related disorders; 2017 Oct

      https://pubmed.ncbi.nlm.nih.gov/29055456/

    12. Bayani Uttara, Ajay V Singh, Paolo Zamboni, RT Mahajan; "Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options"; Current neuropharmacology; 2009 Mar

      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724665/

    13. Elizabeth A. Varga, Amy C. Sturm, Caron P. Misita, Stephan Moll; "Homocysteine and MTHFR Mutations: Relation to Thrombosis and Coronary Artery Disease"; Circulation, Vol. 111, No. 19; 2005 May

      https://www.ahajournals.org/doi/10.1161/01.CIR.0000165142.37711.E7

    14. Y S Haviv, V Shpichinetsky, N Goldschmidt, I Abou Atta, A Ben-Yehuda, G Friedman; "The common mutations C677T and A1298C in the human methylenetetrahydrofolate reductase gene are associated with hyperhomocysteinemia and cardiovascular disease in hemodialysis patients"; Nephron; 2002 Sep

      https://pubmed.ncbi.nlm.nih.gov/12187094/

    15. Fakhraddin Naghibalhossaini, Hesam Ehyakonandeh, Alireza Nikseresht, Eskandar Kamali; "Association Between MTHFR Genetic Variants and Multiple Sclerosis in a Southern Iranian Population"; International journal of molecular and cellular medicine; 2015 Spring

      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499570/

    16. Lotti Tajouri, Virginie Martin, Claudia Gasparini, Micky Ovcaric, Rob Curtain, Rod A Lea, Larisa M Haupt, Peter Csurhes, Michael P Pender, Lyn R Griffiths; "Genetic investigation of methylenetetrahydrofolate reductase (MTHFR) and catechol-O-methyl transferase (COMT) in multiple sclerosis"; Brain research bulletin; 2006 Apr

      https://pubmed.ncbi.nlm.nih.gov/16564429/

    17. Fakhraddin Naghibalhossaini, Hesam Ehyakonandeh, Alireza Nikseresht, Eskandar Kamali; "Association Between MTHFR Genetic Variants and Multiple Sclerosis in a Southern Iranian Population"; International journal of molecular and cellular medicine; 2015 Spring

      https://pubmed.ncbi.nlm.nih.gov/26261797/

    18. I S Weisberg, P F Jacques, J Selhub, A G Bostom, Z Chen, R Curtis Ellison, J H Eckfeldt, R Rozen; "The 1298A-->C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine"; Atherosclerosis; 2001 Jun

      https://pubmed.ncbi.nlm.nih.gov/11395038/

    19. Sudabeh Alatab, Arash Hossein-nezhad, Khadijeh Mirzaei, Fatemeh Mokhtari, Gholamreza Shariati, Azam Najmafshar; "Inflammatory Profile, Age of Onset, and the MTHFR Polymorphism in Patients with Multiple Sclerosis"; Journal of Molecular Neuroscience, Vol. 44; 2010 Dec

      https://link.springer.com/article/10.1007/s12031-010-9486-y

    20. Najiba Fekih Mrissa, Meriem Mrad, Sarra Klai, Jamel Zaouali, Aycha Sayeh, Chakib Mazigh, Brahim Nsiri, Salem Machgoul, Nasreddine Gritli, Ridha Mrissa; "Association of methylenetetrahydrofolate reductase A1298C polymorphism but not of C677T with multiple sclerosis in Tunisian patients"; Clinical neurology and neurosurgery; 2013 Sep

      https://pubmed.ncbi.nlm.nih.gov/23523621/

    21. Lotti Tajouri, Virginie Martin, Claudia Gasparini, Micky Ovcaric, Rob Curtain, Rod A Lea, Larisa M Haupt, Peter Csurhes, Michael P Pender, Lyn R Griffiths; "Genetic investigation of methylenetetrahydrofolate reductase (MTHFR) and catechol-O-methyl transferase (COMT) in multiple sclerosis"; Brain research bulletin; 2006 Apr

      https://pubmed.ncbi.nlm.nih.gov/16564429/

    22. Christina Tryfonos, Maria Mantzorou, Dimitris Fotiou, Michael Vrizas, Konstantinos Vadikolias, Eleni Pavlidou, Constantinos Giaginis; "Dietary Supplements on Controlling Multiple Sclerosis Symptoms and Relapses: Current Clinical Evidence and Future Perspectives"; Medicines; 2019 Sep

      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789617/

    23. Khalid M Al-Batayneh, Mazhar Salim Al Zoubi, Murad Shehab, Bahaa Al-Trad, Khaldon Bodoor, Wesam Al Khateeb, Alaa A A Aljabali, Mohammad Al Hamad, Greg Eaton; "Association between MTHFR 677C>T Polymorphism and Vitamin B12 Deficiency: A Case-control Study"; Journal of medical biochemistry; 2018 Apr

      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294092/

    24. Bruce HR Wolffenbuttel, Hanneke JCM Wouters, M Rebecca Heiner-Fokkema, Melanie M van der Klauw; "The Many Faces of Cobalamin (Vitamin B12) Deficiency"; Mayo Clinic proceedings. Innovations, quality & outcomes.; 2019 May

      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543499/

    25. Antonio Bascones-Martinez, Riikka Mattila, Rafael Gomez-Font, Jukka H Meurman; "Immunomodulatory drugs: Oral and systemic adverse effects"; Medicina oral, patología oral y cirugía bucal; 2013 Aug

      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909428/

    26. A Dhur, P Galan, S Hercberg; "Folate status and the immune system"; Progress in food & nutrition science; 1991

      https://pubmed.ncbi.nlm.nih.gov/1887065/

    27. Ekaterina Dubchenko, Alexander Ivanov, Natalia Spirina, Nina Smirnova, Mikhail Melnikov, Alexey Boyko, Evgeniy Gusev, Aslan Kubatiev; "Hyperhomocysteinemia and Endothelial Dysfunction in Multiple Sclerosis"; Brain Sci.; 2020

      https://www.mdpi.com/2076-3425/10/9/637

    28. Edward Reynolds; "Vitamin B12, folic acid, and the nervous system"; The Lancet Neurology, Vol. 5, Iss. 11, 949 - 960; 2006 Nov

      https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(06)70598-1/fulltext

    29. Juan Ni, Ling Zhang, Tao Zhou, Wei-Jiang Xu, Jing-Lun Xue, Neng Cao, Xu Wang; "Association between the MTHFR C677T polymorphism, blood folate and vitamin B12 deficiency, and elevated serum total homocysteine in healthy individuals in Yunnan Province, China"; Journal of the Chinese Medical Association Vol. 80, Iss. 3; 2017 Mar

      https://www.sciencedirect.com/science/article/pii/S1726490116302179

    30. Olga A Balashova, Olesya Visina, Laura N Borodinsky; "FOLATE ACTION IN NERVOUS SYSTEM DEVELOPMENT AND DISEASE"; Developmental neurobiology; 2019 Apr

      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867258/

    31. Tapan Behl, Dapinder Kaur, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Gokhan Zengin, Felicia Liana Andronie-Cioara, Mirela Marioara Toma, Simona Bungau, Adrian Gheorghe Bumbu; "Role of Monoamine Oxidase Activity in Alzheimer’s Disease: An Insight into the Therapeutic Potential of Inhibitors"; Molecules; 2021 Jun

      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234097/

    32. E H Reynolds; "Multiple sclerosis and vitamin B12 metabolism"; Journal of neurology, neurosurgery, and psychiatry; 1992 May

      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC489070/

    33. Ehsan Nozari, Saied Ghavamzadeh, Nazanin Razazian; "The Effect of Vitamin B12 and Folic Acid Supplementation on Serum Homocysteine, Anemia Status and Quality of Life of Patients with Multiple Sclerosis"; Clinical nutrition research; 2019 Jan

      https://pubmed.ncbi.nlm.nih.gov/30746346/

    34. Alberto Ascherio, Kassandra L Munger, Jan D Lünemann; "The initiation and prevention of multiple sclerosis"; Nature reviews. Neurology; 2015 Jun

      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467212/

    35. M A Hernán, M J Olek, A Ascherio; "Cigarette smoking and incidence of multiple sclerosis"; American journal of epidemiology; 2001 Jul

      https://pubmed.ncbi.nlm.nih.gov/11427406/%5C

    36. J K Gupta, A P Ingegno, A W Cook, L P Pertschuk; "Multiple sclerosis and malabsorption"; The American journal of gastroenterology; 1977 Dec

      https://pubmed.ncbi.nlm.nih.gov/612212/

    37. S A Kanevskaia, A S Kravets, E V Slesarenko, V I Shevchenko, N V Tkachenko; "[Folic acid in the combined treatment of patients with disseminated sclerosis and chronic gastritis]"; Vrachebnoe delo; 1990 Apr

      https://pubmed.ncbi.nlm.nih.gov/2275187/

    38. S J van Rensburg, M J Kotze, D Hon, P Haug, J Kuyler, M Hendricks, J Botha, F C V Potocnik, T Matsha, R T Erasmus; "Iron and the folate-vitamin B12-methylation pathway in multiple sclerosis"; Metabolic brain disease; 2006 Sep

      https://pubmed.ncbi.nlm.nih.gov/16729250/

    39. Kassandra L Munger, Lynn I Levin, Bruce W Hollis, Noel S Howard, Alberto Ascherio; "Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis"; JAMA; 2006 Dec

      https://pubmed.ncbi.nlm.nih.gov/17179460/

    40. Maša Vidmar Golja, Alenka Šmid, Nataša Karas Kuželički, Jurij Trontelj, Ksenija Geršak, Irena Mlinarič-Raščan; "Folate Insufficiency Due to MTHFR Deficiency Is Bypassed by 5-Methyltetrahydrofolate"; Journal of clinical medicine; 2020 Sep

      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564482/

    41. --

      https://i.trade-cloud.com.cn/upload/6405/file/20210929/english-version-magnafolate-enhancing-immunity_524485.pdf

    42. Cristiana Paul, David M Brady; "Comparative Bioavailability and Utilization of Particular Forms of B12 Supplements With Potential to Mitigate B12-related Genetic Polymorphisms"; Integrative medicine; 2017 Feb

      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312744/

    43. Cristiana Paul, David M Brady; "Comparative Bioavailability and Utilization of Particular Forms of B12 Supplements With Potential to Mitigate B12-related Genetic Polymorphisms"; Integrative medicine; 2017 Feb

      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312744/

    Katie Stone - Naturopath

    About the Author

    Katie is a qualified Naturopath (BNatMed) and freelance writer from New Zealand. She specializes in all things health and wellness, particularly dietary supplements and nutrition. Katie is also a dedicated runner and has completed more half-marathons than she can count!

    Related Articles

    What is the Best Form of B12 for You?

    What is the Best Form of B12 for You?

    Written By: Jamie Hope - Founder of Methyl-Life

    Browse Categories